Pyloric Hypertrophy

Pyloric hypertrophy, also known as pyloric stenosis or hypertrophic pyloric gastropathy, is a condition characterized by thickening of the circular smooth muscle layer of the pyloric sphincter, leading to partial or complete obstruction of gastric outflow. This results in delayed gastric emptying, chronic vomiting, and progressive weight loss. The condition can be congenital (primarily in young animals, especially brachycephalic breeds) or acquired (usually in older animals, often secondary to chronic gastritis or neoplasia). Pyloric hypertrophy is classified into three types: muscular hypertrophy (most common), mucosal hypertrophy, and a mixed form. The obstruction can be functional (due to spasm) or mechanical (due to anatomical thickening). In severe cases, it can lead to gastric dilatation, electrolyte imbalances, and malnutrition.

The exact etiology of pyloric hypertrophy is not fully understood, but several factors are implicated. Congenital pyloric stenosis is believed to have a genetic predisposition, particularly in brachycephalic breeds such as Boxers, Boston Terriers, and Bulldogs, where it may be present from birth. Acquired pyloric hypertrophy is often associated with chronic gastritis, which can be caused by Helicobacter pylori infection, dietary indiscretion, or chronic use of non-steroidal anti-inflammatory drugs (NSAIDs). Other potential causes include gastric neoplasia (e.g., leiomyoma, leiomyosarcoma, adenocarcinoma) that induces secondary hypertrophy, and endocrine disorders such as hypergastrinemia (e.g., due to gastrinoma) which stimulates smooth muscle growth. Chronic pyloric spasm due to autonomic dysfunction or stress may also contribute. In some cases, the condition is idiopathic.

Pyloric hypertrophy is most commonly diagnosed in dogs, with a higher prevalence in brachycephalic breeds (e.g., Boxer, Bulldog, Boston Terrier) and small breeds (e.g., Lhasa Apso, Shih Tzu, Pekingese). Congenital pyloric stenosis typically presents in puppies under 6 months of age, while acquired pyloric hypertrophy is seen in middle-aged to older dogs (mean age 7-8 years). Cats are less commonly affected, but Siamese and Persian breeds may be predisposed. There is no strong sex predilection, though some studies suggest a slight male predominance. The condition is relatively uncommon overall, but it is an important differential for chronic vomiting in dogs. Geographic variation is not significant, but brachycephalic breeds are more prevalent in certain regions.

The pathophysiology of pyloric hypertrophy involves progressive thickening of the pyloric smooth muscle, leading to mechanical obstruction of gastric outflow. This thickening may be due to smooth muscle hyperplasia or hypertrophy, often accompanied by mucosal hyperplasia and edema. The obstruction causes increased intragastric pressure, leading to gastric dilatation, delayed emptying, and chronic vomiting. The vomiting leads to loss of gastric acid (hydrochloric acid) and electrolytes, particularly chloride, potassium, and sodium, resulting in hypochloremic, hypokalemic metabolic alkalosis. Chronic vomiting also causes dehydration and malnutrition. The increased gastric pressure may lead to gastritis, esophagitis (due to reflux of gastric contents), and aspiration pneumonia. In severe cases, gastric ischemia and necrosis can occur. The condition may also be associated with abnormal pyloric sphincter function, including incoordination or spasm, which exacerbates the obstruction.

Predisposing factors for pyloric hypertrophy include breed predisposition (brachycephalic and small breeds), genetic factors (congenital form), age (congenital in puppies, acquired in older dogs), and chronic gastritis. Dietary factors such as feeding large meals infrequently may contribute to gastric distension and pyloric dysfunction. Concurrent diseases such as inflammatory bowel disease, gastric neoplasia, and endocrine disorders (e.g., gastrinoma) can predispose to acquired pyloric hypertrophy. Chronic use of medications that affect gastric motility or increase gastric acid secretion (e.g., anticholinergics, corticosteroids) may also be risk factors. Stress and autonomic nervous system imbalances may lead to pyloric spasm, which can progress to hypertrophy.

Clinical signs of pyloric hypertrophy are primarily related to chronic vomiting, which is often projectile and occurs shortly after eating. The vomitus may contain undigested food, bile, or foam. Other signs include weight loss, poor body condition, decreased appetite, and lethargy. In severe cases, signs of dehydration, weakness, and electrolyte imbalances may be evident. Physical examination may reveal a palpable abdominal mass in the cranial abdomen (in some cases), signs of dehydration (decreased skin turgor, dry mucous membranes), and poor body condition. In congenital cases, puppies may fail to thrive and have a distended abdomen. Chronic vomiting can lead to esophagitis, with signs of regurgitation and dysphagia. Aspiration pneumonia may cause coughing and respiratory distress. In advanced cases, gastric dilatation may be palpable.

Differential diagnoses for pyloric hypertrophy include: 1) Gastric foreign body: acute onset, radiographic or endoscopic evidence of a foreign object. 2) Gastric neoplasia (e.g., adenocarcinoma, leiomyosarcoma): older animals, weight loss, mass on imaging, biopsy confirms. 3) Chronic gastritis: may have similar signs, but imaging shows normal pylorus, endoscopy with biopsy differentiates. 4) Gastric ulceration: hematemesis, melena, response to antacids, endoscopy reveals ulcers. 5) Pylorospasm: functional obstruction, may respond to antispasmodics, imaging shows no anatomical thickening. 6) Gastric dilatation-volvulus (GDV): acute, severe distension, shock, radiographs show gas-filled stomach with pyloric displacement. 7) Eosinophilic gastroenteritis: peripheral eosinophilia, biopsy shows eosinophilic infiltration. 8) Inflammatory bowel disease (IBD): chronic vomiting, diarrhea, biopsy shows lymphocytic-plasmacytic infiltration. 9) Pancreatitis: abdominal pain, elevated lipase/PLI, imaging of pancreas. 10) Hiatal hernia: regurgitation, thoracic radiographs or fluoroscopy.

The diagnostic algorithm for pyloric hypertrophy begins with a thorough history and physical examination, focusing on chronic vomiting and breed predisposition. Initial laboratory tests include a complete blood count (CBC), serum biochemistry profile, and urinalysis to assess hydration, electrolyte status, and rule out metabolic causes. Abdominal radiographs may show a distended stomach with retained ingesta, but are often non-specific. Abdominal ultrasonography is the next step, which can reveal thickening of the pyloric wall (typically >5 mm in dogs) and delayed gastric emptying. If available, contrast radiography (barium meal) can demonstrate delayed gastric emptying and a narrowed pyloric canal. Endoscopy is the gold standard for diagnosis, allowing direct visualization of the pylorus, assessment of mucosal abnormalities, and collection of biopsies to rule out neoplasia or inflammation. In some cases, fluoroscopy can assess gastric motility. If endoscopy is not available, exploratory laparotomy with full-thickness biopsy may be necessary. Advanced imaging such as CT or MRI may be used to evaluate for masses or extramural compression.

Laboratory findings in pyloric hypertrophy are often consistent with chronic vomiting and dehydration. Hematology may show hemoconcentration (increased packed cell volume, total protein) due to dehydration, and stress leukogram (neutrophilia, lymphopenia) in chronic illness. Serum biochemistry typically reveals hypochloremia, hypokalemia, and metabolic alkalosis (elevated bicarbonate, increased base excess). Blood urea nitrogen (BUN) and creatinine may be mildly elevated due to prerenal azotemia. Liver enzymes may be mildly elevated due to hepatic lipidosis or concurrent disease. Urinalysis may show concentrated urine (high specific gravity) and possibly ketonuria if the animal is anorexic. Blood gas analysis confirms metabolic alkalosis with compensatory respiratory acidosis (hypoventilation). Specific biomarkers such as canine pancreatic lipase immunoreactivity (cPLI) may be normal, but can be elevated if pancreatitis is present. In cases of chronic gastritis, Helicobacter pylori testing (fecal antigen, PCR, or biopsy) may be positive.

Radiography: Abdominal radiographs may show a gas- or fluid-distended stomach, with retained ingesta even after fasting. In some cases, a soft tissue mass may be visible in the pyloric region. Contrast radiography (barium series) reveals delayed gastric emptying (barium remaining in the stomach for >6 hours), a narrowed pyloric canal, and a thickened pyloric wall. Ultrasonography: Abdominal ultrasound is highly useful, showing a thickened pyloric wall (typically >5 mm in dogs, >4 mm in cats), often with a target-like appearance. The muscular layer may be hypoechoic, and the mucosa may be hyperechoic. Doppler ultrasound can assess blood flow. Computed Tomography (CT): CT provides detailed cross-sectional images, allowing precise measurement of pyloric wall thickness and evaluation of extramural masses. It is particularly useful for surgical planning. Magnetic Resonance Imaging (MRI): MRI is less commonly used but can provide excellent soft tissue contrast. Endoscopy: Endoscopy is both diagnostic and therapeutic, allowing direct visualization of the pylorus, assessment of mucosal erythema, erosions, or masses, and collection of biopsies. Fluoroscopy: Fluoroscopy with barium can assess gastric motility and pyloric function in real time.

Cytology: Fine needle aspiration (FNA) of the pyloric region may be performed under ultrasound guidance, but is often non-diagnostic due to the muscular nature of the lesion. If a mass is present, FNA may reveal spindle cells (smooth muscle) or neoplastic cells. Histopathology: Full-thickness biopsy is the gold standard for diagnosis. Histological findings include hypertrophy and hyperplasia of the circular smooth muscle layer, often with fibrosis. The mucosa may show signs of chronic gastritis, including lymphocytic-plasmacytic infiltration, glandular atrophy, or intestinal metaplasia. In cases of mucosal hypertrophy, the mucosa is thickened with elongated glands. Special stains (e.g., Masson's trichrome) can highlight fibrosis. Immunohistochemistry may be used to differentiate smooth muscle tumors (positive for smooth muscle actin) from other neoplasms.

Treatment of pyloric hypertrophy is primarily surgical, with pyloroplasty (e.g., Fredet-Ramstedt pyloromyotomy, Heineke-Mikulicz pyloroplasty) or pyloric resection (antrectomy) being the most common procedures. Medical management may be attempted in mild cases or as a temporary measure, including: 1) Dietary modification: feeding small, frequent, low-fat, easily digestible meals to reduce gastric volume and stimulate gastric emptying. 2) Antacids: proton pump inhibitors (e.g., omeprazole 0.7-1.0 mg/kg PO q12h) or H2 blockers (e.g., famotidine 0.5-1 mg/kg PO q12h) to reduce gastric acidity and prevent esophagitis. 3) Prokinetic agents: metoclopramide (0.2-0.4 mg/kg PO/SC q8h) or cisapride (0.5 mg/kg PO q8h) to enhance gastric motility, though cisapride is not widely available. 4) Antiemetics: maropitant (1 mg/kg SC q24h or 2 mg/kg PO q24h) to control vomiting. 5) Fluid therapy: correction of dehydration and electrolyte imbalances (e.g., 0.9% NaCl with potassium chloride supplementation). Surgical treatment is indicated for moderate to severe cases, especially when medical management fails. Postoperative care includes pain management (e.g., opioids, NSAIDs with caution), antibiotics if indicated, and gradual reintroduction of food.

The prognosis for pyloric hypertrophy is generally good to excellent with surgical intervention, especially in congenital cases. Most animals show resolution of vomiting and improvement in body condition within days to weeks postoperatively. The prognosis is guarded for acquired cases associated with neoplasia or severe concurrent disease. Complications such as surgical site dehiscence, infection, or recurrence of obstruction are rare but possible. Negative prognostic indicators include the presence of gastric neoplasia, severe debilitation, and delayed diagnosis. With appropriate treatment, the long-term survival is excellent for benign cases, with many animals living a normal lifespan.

Postoperative follow-up is essential to monitor recovery and detect complications. Re-check examinations are recommended at 1-2 weeks, 4-6 weeks, and 3-6 months after surgery. During these visits, assess body weight, appetite, and vomiting frequency. Serial laboratory tests (CBC, biochemistry, electrolytes) may be indicated to ensure metabolic normalization. Imaging (ultrasound or contrast radiography) may be repeated at 4-6 weeks to confirm normal gastric emptying. Long-term management includes feeding a high-quality, easily digestible diet in small, frequent meals. Owners should be advised to monitor for signs of recurrence, such as vomiting or weight loss. In cases of underlying chronic gastritis, ongoing medical therapy (e.g., antacids, prokinetics) may be necessary. Regular dental care and avoidance of NSAIDs may help prevent recurrence.

Pearls: 1) Always consider pyloric hypertrophy in young brachycephalic dogs with chronic vomiting. 2) Ultrasonography is a non-invasive, highly sensitive diagnostic tool; a pyloric wall thickness >5 mm in dogs is highly suggestive. 3) Endoscopy allows both diagnosis and biopsy, which is essential to rule out neoplasia. 4) Surgical pyloroplasty is curative in most cases; early intervention improves outcomes. 5) Correct electrolyte imbalances (hypochloremia, hypokalemia, alkalosis) before surgery to reduce anesthetic risk. Pitfalls: 1) Misdiagnosing as simple gastritis and treating medically for too long, delaying definitive therapy. 2) Failing to perform biopsies during endoscopy, missing underlying neoplasia. 3) Overlooking concurrent esophagitis or aspiration pneumonia. 4) Using metoclopramide in cases of mechanical obstruction, which can worsen the condition. 5) Not monitoring for postoperative complications such as gastric ulceration or stricture.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are recommended for medical management and supportive care of pyloric hypertrophy: 1) Proton pump inhibitors: Omeprazole 0.7-1.0 mg/kg PO q12h (dogs), 0.7-1.0 mg/kg PO q12h (cats); Pantoprazole 0.7-1.0 mg/kg IV q24h for severe cases. 2) H2 receptor antagonists: Famotidine 0.5-1 mg/kg PO/IV q12h; Ranitidine 2 mg/kg PO q12h (less preferred). 3) Prokinetics: Metoclopramide 0.2-0.4 mg/kg PO/SC q8h (dogs), 0.2-0.4 mg/kg PO/SC q8h (cats); Cisapride 0.5 mg/kg PO q8h (dogs), 0.5 mg/kg PO q8h (cats) (if available). 4) Antiemetics: Maropitant 1 mg/kg SC q24h (dogs), 2 mg/kg PO q24h (dogs); 1 mg/kg SC q24h (cats), 2 mg/kg PO q24h (cats). 5) Antacids: Aluminum hydroxide 10-30 mg/kg PO q8h (dogs); Calcium carbonate 10-20 mg/kg PO q8h (dogs). 6) Fluid therapy: 0.9% NaCl with potassium chloride (20-30 mEq/L) at maintenance rates (60-100 ml/kg/day) to correct dehydration and hypokalemia. 7) Antibiotics: Only if concurrent infection (e.g., aspiration pneumonia) is present; e.g., Amoxicillin-clavulanate 12.5-25 mg/kg PO q12h. 8) Analgesics: Postoperative pain management with opioids (e.g., buprenorphine 0.01-0.02 mg/kg IV/IM q8h) or NSAIDs (e.g., carprofen 2.2 mg/kg PO q12h) with caution. Dosages should be adjusted for renal or hepatic impairment, and contraindications (e.g., NSAIDs in dehydrated animals) must be considered.

Evidence-based literature on pyloric hypertrophy is limited, but several studies and reviews provide guidance. A retrospective study by Bellenger et al. (1990) reported successful outcomes in 85% of dogs undergoing pyloroplasty for pyloric stenosis. Another study by Matthiesen et al. (1993) compared surgical techniques and found that Fredet-Ramstedt pyloromyotomy had fewer complications than Heineke-Mikulicz pyloroplasty. A consensus statement from the ACVIM on chronic vomiting in dogs (2013) recommends surgical intervention for confirmed pyloric hypertrophy. A study by Leib et al. (1993) evaluated the use of ultrasonography for diagnosis, reporting a sensitivity of 90% when pyloric wall thickness >5 mm. Regarding medical management, a study by Hall et al. (2000) showed that omeprazole was more effective than famotidine in reducing gastric acidity. There are no large randomized controlled trials, but expert consensus supports early surgical correction for optimal outcomes. Further research is needed to evaluate the role of Helicobacter pylori in acquired pyloric hypertrophy and the efficacy of prokinetic agents.